The aim of the study is to investigate pulmonary hemodynamics at rest and during exercise in
patients before and after kidney transplantation.
The goal of this patient registry is to learn about the natural history in patients with
chronic thromboembolic disease (CTD) and/or chronic thromboembolic pulmonary hypertension
(CTEPH). The main question[s] it aims to answer are:
- Long-term outcome after various types of treatment, including medication, balloon
pulmonary angioplasty, and pulmonary endarterectomy
- Effect of treatment on patient's quality of life and exercise tolerance Participants
will be followed longitudinally to assess their health outcomes and quality of life via
chart review and health quality surveys.
Cognitive behavioral therapy (CBT-I) is a common treatment for insomnia that does not use
medications. While CBT-I is effective for insomnia, it does not tend to improve the waking
symptom of fatigue. Another treatment, Bright Light Therapy, is used for treating seasonal
depression and sleep disorders, and may improve fatigue and physical activity in individuals
with PAH. The purpose of this study to assess the effects of Bright Light Therapy compared to
CBT-I to treat insomnia and fatigue in patients with PAH.
Though graded balloon-atrial-septostomy (BAS) has been accepted as an effective palliative
therapy for severe pulmonary arterial hypertension, spontaneous closure of septostomy is not
uncommon. Radiofrequency-catheter-ablation (RFA), which has the potential to cause
irreversible damage around the rim of created inter-atrial communication, might contribute to
prevent the spontaneous closure. In patients with severe pulmonary arterial hypertension, the
combined use of RFA and BAS (CURB) is investigated to create a stable inter-atrial
The objective of this observational study is to compare cardiac output evaluation by the
Direct Fick method, Indirect Fick method and Thermodiluition in pulmonary hypertension (PH)
patients undergoing right heart catheterization (RHC).
The main questions it aims to answer are:
- Are these methods interchangeable?
- Can possible discrepancies influence risk stratification and therapeutic management of
PH patients? All consecutive patients aged ≥18 years, referred for RHC for suspected PH,
will be included. Exclusion criteria will be contraindications to RHC, cardiac shunts
and failure to obtain...
The overarching goal of this study is to examine the acute vasoreactive response to both
inhaled nitric oxide and inhaled epoprostenol across both traditionally and non-traditionally
interrogated phenotypes in PH, and to further characterize the relationship of vasoreactivity
to disease severity and PH phenotype.
In view of the manifold options for mono- and combination therapy that have now emerged for
patients with pulmonary (arterial) hypertension (PH/PAH), controlled clinical trials can only
provide part of the information needed for optimal management. In order to gather adequate
data on PAH/PH treatment in routine clinical care, the ongoing COMPERA registry prospectively
documents consecutive patients with newly initiated treatment of PAH/PAH since May 2007. The
internet-based registry fulfills high quality standards through several measures (planned
minimum centre contribution of at least 10 patients per year, automated plausibility checks
The prevalence of critical ab extrinsic compression of left main coronary artery (LMCA) is
very high in patients with pulmonary arterial hypertension (PAH) symptomatic for angina (up
to 40% according to a recent study of 121 patients with PAH). The element that most of all
correlates with the degree of coronary stenosis is the diameter of the pulmonary artery (PA).
In particular, a diameter ≥ 40 mm has a sensitivity of 83% and a specificity of 70% in
patients with angina. Critical stenosis of LMCA is a risk factor for sudden death and in
these condition percutaneous coronary angioplasty with stent implantation has proven to be a
To address the knowledge gap that exists among providers resulting in underdiagnosis of
chronic thromboembolic pulmonary hypertension (CTEPH), the investigators have devised this
400-patient single-center Quality Improvement Initiative in the form of a randomized
controlled trial of an EPIC Best Practice Advisory (BPA) on-screen alert versus no
notification to increase echocardiographic screening for CTEPH and the diagnosis of CTEPH in
patients with prior pulmonary embolism (PE) and symptoms/signs suggestive of pulmonary
hypertension or recent pulmonary testing suggesting unexplained respiratory symptoms at 3
Currently, the gold standard method to estimate CO in patients with PAH or RV dysfunction is
pulmonary artery catheter (PAC), however, the invasiveness and complexity of PAC has limited
its usefulness in many clinical scenarios. By measuring the thoracic electrical bioimpedance,
electrical cardiometry (EC) technique has been reported to noninvasively estimate cardiac
output (CO) and other parameters related to cardiac contractility and fluid status in various
cardiovascular disorders. However, in patients with pulmonary arterial hypertension (PAH)
and/or right ventricular (RV) dysfunction, few study has been reported. The aim of this...